CDK12 Inactivation Attenuates Prostate Cancer Progression by Inhibiting BNIP3-Mediated Mitophagy

Abstract

Mitochondrial stress-induced mitophagy plays a critical role to maintain cellular homeostasis; however, in cancer cells, this process may also contribute to drug resistance. Our previous work identified CDK12 as a critical regulator of prostate cancer (PCa) cell survival under sustained enzalutamide exposure, though the precise mechanism remains to be elucidated. In this study, we hypothesize that CDK12 plays a key role in mitophagy regulation under mitochondrial stress, potentially modulating PCa cell resistance to enzalutamide, the first-line clinical medication in PCa therapy. Utilising multiple in vitro PCa cell models, we demonstrate that both CDK12 knockdown and pharmacological inhibition with THZ531 impaired mitophagy following treatment with enzalutamide and mitophagy inducer CCCP. Mechanistically, our finding reveal that CDK12 inhibition disrupts FOXO3-induced BNIP3 transcription, thereby preventing receptor-mediated mitophagy and sensitising PCa cells to enzalutamide. This study identifies the CDK12-FOXO3-BNIP3 pathway as a novel regulatory mechanism governing mitophagy under mitochondrial stress. Importantly, these results underscore CDK12's role in preserving mitochondrial function and promoting PCa cell survival during enzalutamide treatment. These findings highlight the therapeutic potential of targeting the CDK12-BNIP3-mitophagy axis in combination with antiandrogen therapies, offering a promising strategy to overcome drug resistance in PCa and improve clinical outcomes.

Keywords

BNIP3 / CDK12 / enzalutamide treatment / mitophagy / prostate cancer

References

[1] K. Chi, S. J. Hotte, A. M. Joshua, et al., “Treatment of mCRPC in the AR-Axis-Targeted Therapy-Resistant State,” Annals of Oncology 26, no. 10 (2015): 2044–2056, https://doi.org/10.1093/annonc/mdv267.

[2] H. I. Scher, K. Fizazi, F. Saad, et al., “Increased Survival With Enzalutamide in Prostate Cancer After Chemotherapy,” New England Journal of Medicine 367, no. 13 (2012): 1187–1197, https://doi.org/10.1056/NEJMoa1207506.

[3] D. A. Quigley, H. X. Dang, S. G. Zhao, et al., “Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer,” Cell 175, no. 3 (2018): 889, https://doi.org/10.1016/j.cell.2018.10.019.

[4] T. K. Le, Q. H. Duong, V. Baylot, et al., “Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments,” Cancers 15, no. 20 (2023): 5047, https://doi.org/10.3390/cancers15205047.

[5] S. T. Tagawa, E. S. Antonarakis, A. Gjyrezi, et al., “Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates With Outcomes to Taxane Therapy in Men With Metastatic Prostate Cancer Treated in TAXYNERGY,” Clinical Cancer Research 25, no. 6 (2019): 1880–1888, https://doi.org/10.1158/1078-0432.CCR-18-0320.

[6] Y. Hou, Z. Zhao, P. Li, et al., “Combination Therapies With Wnt Signaling Inhibition: A Better Choice for Prostate Cancer Treatment,” Biochimica et Biophysica Acta, Reviews on Cancer 1879, no. 6 (2024): 189186, https://doi.org/10.1016/j.bbcan.2024.189186.

[7] D. Gao, Y. Shen, L. Xu, et al., “Acetate Utilization Promotes Hormone Therapy Resistance in Prostate Cancer Through Neuroendocrine Differentiation,” Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 77 (2024): 101158, https://doi.org/10.1016/j.drup.2024.101158.

[8] J. Wang, L. Zeng, N. Wu, et al., “Inhibition of Phosphoglycerate Dehydrogenase Induces Ferroptosis and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells,” Drug Resistance Updates 70 (2023): 100985, https://doi.org/10.1016/j.drup.2023.100985.

[9] J. Li, Q. Lin, X. Shao, et al., “HIF1α-BNIP3-Mediated Mitophagy Protects Against Renal Fibrosis by Decreasing ROS and Inhibiting Activation of the NLRP3 Inflammasome,” Cell Death & Disease 14, no. 3 (2023): 200, https://doi.org/10.1038/s41419-023-05587-5.

[10] H. M. Ni, J. A. Williams, and W. X. Ding, “Mitochondrial Dynamics and Mitochondrial Quality Control,” Redox Biology 4 (2015): 6–13, https://doi.org/10.1016/j.redox.2014.11.006.

[11] A. Zeb, V. Choubey, R. Gupta, et al., “A Novel Role of KEAP1/PGAM5 Complex: ROS Sensor for Inducing Mitophagy,” Redox Biology 48 (2021): 102186, https://doi.org/10.1016/j.redox.2021.102186.

[12] Y. Yuan, Y. Zheng, X. Zhang, et al., “BNIP3L/NIX-Mediated Mitophagy Protects Against Ischemic Brain Injury Independent of PARK2,” Autophagy 13, no. 10 (2017): 1754–1766, https://doi.org/10.1080/15548627.2017.1357792.

[13] M. N. Quinsay, R. L. Thomas, Y. Lee, and A. B. Gustafsson, “Bnip3-Mediated Mitochondrial Autophagy Is Independent of the Mitochondrial Permeability Transition Pore,” Autophagy 6, no. 7 (2010): 855–862, https://doi.org/10.4161/auto.6.7.13005.

[14] Z. J. Fu, Z. Y. Wang, L. Xu, et al., “HIF-1α-BNIP3-Mediated Mitophagy in Tubular Cells Protects Against Renal Ischemia/Reperfusion Injury,” Redox Biology 36 (2020): 101671, https://doi.org/10.1016/j.redox.2020.101671.

[15] N. Nikesitch, E. Beraldi, F. Zhang, et al., “Chaperone-Mediated Autophagy Promotes PCa Survival During ARPI Through Selective Proteome Remodeling,” Oncogene 42, no. 10 (2023): 748–758, https://doi.org/10.1038/s41388-022-02573-7.

[16] J. Han, J. Zhang, W. Zhang, et al., “Abiraterone and MDV3100 Inhibits the Proliferation and Promotes the Apoptosis of Prostate Cancer Cells Through Mitophagy,” Cancer Cell International 19, no. 1 (2019): 332, https://doi.org/10.1186/s12935-019-1021-9.

[17] L. Yin, Y. Ye, L. Zou, et al., “AR Antagonists Develop Drug Resistance Through TOMM20 Autophagic Degradation-Promoted Transformation to Neuroendocrine Prostate Cancer,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 204, https://doi.org/10.1186/s13046-023-02776-0.

[18] L. Curti, S. Rohban, N. Bianchi, et al., “CDK12 Controls Transcription at Damaged Genes and Prevents MYC-Induced Transcription-Replication Conflicts,” Nature Communications 15, no. 1 (2024): 7100, https://doi.org/10.1038/s41467-024-51229-5.

[19] Y. Sui, T. Wang, Y. Mei, et al., “Targeting Super-Enhancer-Driven Transcriptional Dependencies Suppresses Aberrant Hedgehog Pathway Activation and Overcomes Smoothened Inhibitor Resistance,” Cancer Research 84, no. 16 (2024): 2690–2706, https://doi.org/10.1158/0008-5472.CAN-23-3306.

[20] Z. Ni, N. Ahmed, S. Nabeel-Shah, et al., “Identifying Human Pre-mRNA Cleavage and Polyadenylation Factors by Genome-Wide CRISPR Screens Using a Dual Fluorescence Readthrough Reporter,” Nucleic Acids Research 52, no. 8 (2024): 4483–4501, https://doi.org/10.1093/nar/gkae240.

[21] H. Liu, K. Liu, and Z. Dong, “Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery,” Cancer Research 81, no. 1 (2021): 18–26, https://doi.org/10.1158/0008-5472.CAN-20-2245.

[22] K. Frei, S. Schecher, T. Daher, et al., “Inhibition of the Cyclin K-CDK12 Complex Induces DNA Damage and Increases the Effect of Androgen Deprivation Therapy in Prostate Cancer,” International Journal of Cancer 154, no. 6 (2024): 1082–1096, https://doi.org/10.1002/ijc.34778.

[23] T. Gong, W. Jaratlerdsiri, J. Jiang, et al., “Genome-Wide Interrogation of Structural Variation Reveals Novel African-Specific Prostate Cancer Oncogenic Drivers,” Genome Medicine 14, no. 1 (2022): 100, https://doi.org/10.1186/s13073-022-01096-w.

[24] Y. M. Wu, M. Cieślik, R. J. Lonigro, et al., “Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer,” Cell 173, no. 7 (2018): 1770–1782.e14, https://doi.org/10.1016/j.cell.2018.04.034.

[25] E. S. Antonarakis, P. I. Velho, W. Fu, et al., “CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors,” JCO Precision Oncology 4 (2020): 370–381, https://doi.org/10.1200/po.19.00399.

[26] H. Zhang, Y. Zhou, Y. Feng, et al., “Cyclin-Dependent Kinase 12 Deficiency Reprogrammes Cellular Metabolism to Alleviate Ferroptosis Potential and Promote the Progression of Castration-Resistant Prostate Cancer,” Clinical and Translational Medicine 14, no. 5 (2024): e1678, https://doi.org/10.1002/ctm2.1678.

[27] Z. Wu, W. Zhang, L. Chen, et al., “CDK12 Inhibition Upregulates ATG7 Triggering Autophagy via AKT/FOXO3 Pathway and Enhances Anti-PD-1 Efficacy in Colorectal Cancer,” Pharmacological Research 201 (2024): 107097, https://doi.org/10.1016/j.phrs.2024.107097.

[28] H. Zou, J. Luo, Y. Guo, et al., “RNA-Binding Protein Complex LIN28/MSI2 Enhances Cancer Stem Cell-Like Properties by Modulating Hippo-YAP1 Signaling and Independently of Let-7,” Oncogene 41, no. 11 (2022): 1657–1672, https://doi.org/10.1038/s41388-022-02198-w.

[29] B. Xu, H. Lei, T. Tong, et al., “Acidity-Actuated Polymer/Calcium Phosphate Hybrid Nanomotor (PCaPmotor) for Penetrating Drug Delivery and Synergistic Anticancer Immunotherapy,” Nano Letters 24, no. 35 (2024): 10724–10733, https://doi.org/10.1021/acs.nanolett.4c01610.

[30] J. Yao, J. Wang, Y. Xu, et al., “CDK9 Inhibition Blocks the Initiation of PINK1-PRKN-Mediated Mitophagy by Regulating the SIRT1-FOXO3-BNIP3 Axis and Enhances the Therapeutic Effects Involving Mitochondrial Dysfunction in Hepatocellular Carcinoma,” Autophagy 18, no. 8 (2021): 1879–1897, https://doi.org/10.1080/15548627.2021.2007027.

[31] H. Lei, Z. Wang, D. Jiang, et al., “CRISPR Screening Identifies CDK12 as a Conservative Vulnerability of Prostate Cancer,” Cell Death & Disease 12, no. 8 (2021), https://doi.org/10.1038/s41419-021-04027-6.

[32] P. Lu, A. Kamboj, S. B. Gibson, and C. M. Anderson, “Poly(ADP-Ribose) Polymerase-1 Causes Mitochondrial Damage and Neuron Death Mediated by Bnip3,” Journal of Neuroscience 34, no. 48 (2014): 15975–15987, https://doi.org/10.1523/jneurosci.2499-14.2014.

[33] M. Tan, Y. Cheng, X. Zhong, et al., “LNK Promotes Granulosa Cell Apoptosis in PCOS via Negatively Regulating Insulin-Stimulated AKT-FOXO3 Pathway,” Aging 13, no. 3 (2021): 4617–4633, https://doi.org/10.18632/aging.202421.

[34] T. C. Westbrook, X. Guan, E. Rodansky, et al., “Transcriptional Profiling of Matched Patient Biopsies Clarifies Molecular Determinants of Enzalutamide-Induced Lineage Plasticity,” Nature Communications 13, no. 1 (2022), https://doi.org/10.1038/s41467-022-32701-6.

[35] F. Menghi, F. P. Barthel, V. Yadav, et al., “The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations,” Cancer Cell 34, no. 2 (2018): 197–210.e5, https://doi.org/10.1016/j.ccell.2018.06.008.

[36] W. Dai, J. Wu, X. Peng, et al., “CDK12 Orchestrates Super-Enhancer-Associated CCDC137 Transcription to Direct Hepatic Metastasis in Colorectal Cancer,” Clinical and Translational Medicine 12, no. 10 (2022), https://doi.org/10.1002/ctm2.1087.

[37] J. C.-Y. Tien, J. Luo, Y. Chang, et al., “CDK12 Loss Drives Prostate Cancer Progression, Transcription-Replication Conflicts, and Synthetic Lethality With Paralog CDK13,” Cell Reports Medicine 5, no. 10 (2024): 101758, https://doi.org/10.1016/j.xcrm.2024.101758.

[38] Y. Chang, X. Wang, J. Yang, et al., “Development of an Orally Bioavailable CDK12/13 Degrader and Induction of Synthetic Lethality With AKT Pathway Inhibition,” Cell Reports Medicine 5, no. 10 (2024): 101752, https://doi.org/10.1016/j.xcrm.2024.101752.

[39] J. Chou, T. M. Robinson, E. A. Egusa, et al., “Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer With PARP Inhibitors,” Clinical Cancer Research 30, no. 23 (2024): 5445–5458, https://doi.org/10.1158/1078-0432.ccr-23-3785.

[40] H. X. Ang, N. Sutiman, X. L. Deng, et al., “Cooperative Regulation of Coupled Oncoprotein Synthesis and Stability in Triple-Negative Breast Cancer by EGFR and CDK12/13,” Proceedings of the National Academy of Sciences 120, no. 38 (2023), https://doi.org/10.1073/pnas.2221448120.

[41] K. Palikaras, E. Lionaki, and N. Tavernarakis, “Mechanisms of Mitophagy in Cellular Homeostasis, Physiology and Pathology,” Nature Cell Biology 20, no. 9 (2018): 1013–1022, https://doi.org/10.1038/s41556-018-0176-2.

[42] Y.-L. He, J. Li, S.-H. Gong, et al., “BNIP3 Phosphorylation by JNK1/2 Promotes Mitophagy via Enhancing Its Stability Under Hypoxia,” Cell Death & Disease 13, no. 11 (2022), https://doi.org/10.1038/s41419-022-05418-z.

[43] A. H. Chourasia and K. F. Macleod, “Tumor Suppressor Functions of BNIP3 and Mitophagy,” Autophagy 11, no. 10 (2015): 1937–1938, https://doi.org/10.1080/15548627.2015.1085136.

[44] T. Kataura, E. G. Otten, Y. Rabanal-Ruiz, et al., “NDP52 Acts as a Redox Sensor in PINK1/Parkin-Mediated Mitophagy,” EMBO Journal 42, no. 5 (2022), https://doi.org/10.15252/embj.2022111372.

[45] L. Sedlackova, G. Kelly, and V. I. Korolchuk, “The pROS of Autophagy in Neuronal Health,” Journal of Molecular Biology 432, no. 8 (2020): 2546–2559, https://doi.org/10.1016/j.jmb.2020.01.020.

[46] G. Kelly, T. Kataura, J. Panek, et al., “Suppressed Basal Mitophagy Drives Cellular Aging Phenotypes That Can Be Reversed by a p62-Targeting Small Molecule,” Developmental Cell 59, no. 15 (2024): 1924–1939.e7, https://doi.org/10.1016/j.devcel.2024.04.020.

[47] J. Qiu, Y. Chen, J. Zhuo, et al., “Urolithin A Promotes Mitophagy and Suppresses NLRP3 Inflammasome Activation in Lipopolysaccharide-Induced BV2 Microglial Cells and MPTP-Induced Parkinson's Disease Model,” Neuropharmacology 207 (2022): 108963, https://doi.org/10.1016/j.neuropharm.2022.108963.

[48] D. Ryu, L. Mouchiroud, P. A. Andreux, et al., “Urolithin A Induces Mitophagy and Prolongs Lifespan in C. Elegans and Increases Muscle Function in Rodents,” Nature Medicine 22, no. 8 (2016): 879–888, https://doi.org/10.1038/nm.4132.

[49] H. Liu, Y. Song, H. Wang, Y. Zhou, M. Xu, and J. Xian, “Deciphering the Power of Resveratrol in Mitophagy: From Molecular Mechanisms to Therapeutic Applications,” Phytotherapy Research 39, no. 3 (2025): 1319–1343, https://doi.org/10.1002/ptr.8433.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.